On August 28, 2026, the University of Miami Miller School of Medicine announced a first-of-its-kind prospective clinical trial evaluating the safety of weekly testosterone cypionate injections in men with low-risk prostate cancer who are being monitored through active surveillance rather than treated immediately. The study is led by Bruce Kava, M.D., professor of urology and director of men's health at the Desai Sethi Urology Institute, with urologic oncology professor Sanoj Punnen, M.D., as DSUI vice chair of research.

Why It Matters

TRT is one of the fastest-growing lanes in male sexual health telehealth, and the prostate cancer contraindication is one of the hardest screening gates in the intake funnel — a categorical exclusion applied to a large, aging, high-propensity population. If a prospective safety trial produces reassuring data, it doesn't just change guidelines; it changes the addressable market for every TRT platform, compounding pharmacy and men's health clinic operating in the space. That said, this is a safety trial in *carefully selected* men under active monitoring, not a green light, and the responsible read is that any expansion would come with mandatory surveillance protocols telehealth platforms are not currently built to deliver. It also lands into a busy year for testosterone policy — an FDA expert panel has already recommended loosening testosterone's Schedule III classification and the agency has opened a pathway toward an approved low-libido indication, both of which Afterglow has tracked. The scientific and regulatory pressure on testosterone access is now moving in the same direction at once.

The trial takes direct aim at one of urology's most durable pieces of received wisdom. For decades, prostate cancer was treated as an absolute contraindication to testosterone replacement — the fear being that supplementing androgens would fuel tumor growth. That belief has softened considerably in clinical practice, but the evidence base has not caught up. "While historical dogma raised concerns about testosterone use in men with prostate cancer, many urologists now believe it can be used safely in carefully selected men on active surveillance with appropriate monitoring," Punnen said. "The challenge is that we still lack high-quality prospective data to know this with certainty."

The population at stake is not small. Miller School figures put low testosterone prevalence at an estimated 20-25% of men over age 55 — precisely the age band where low-risk prostate cancer is most often diagnosed and where active surveillance is now standard of care. Those men are routinely excluded from testosterone replacement, which means the exclusion isn't sparing them treatment side effects so much as leaving them with untreated hypogonadism: reduced energy, diminished sexual function, mood changes, decreased vitality and bone density loss.

Active surveillance itself exists to preserve quality of life — regular PSA testing, MRI imaging and periodic biopsies in place of immediate surgery or radiation, avoiding treatment-related sexual and urinary side effects while maintaining cancer control. Punnen's framing is that testosterone supplementation may belong inside that quality-of-life calculus rather than outside it: "Active surveillance is about safely managing low-risk prostate cancer while preserving quality of life. For some men, maintaining quality of life may include testosterone supplementation."

The Miller School notes the findings could influence future treatment guidelines and reshape how urologists counsel this cohort.

Sources

Update — 2026-08-30

{Initial entry — story first created.}